{"id":"telbivudine-adefovir-dipivoxil","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated creatine kinase"},{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatic flare"},{"rate":null,"effect":"Nephrotoxicity (adefovir)"},{"rate":null,"effect":"Myopathy"}]},"_chembl":{"chemblId":"CHEMBL922","moleculeType":"Small molecule","molecularWeight":"501.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telbivudine is a thymidine nucleoside analog that inhibits HBV reverse transcriptase and reduces viral DNA synthesis. Adefovir dipivoxil is a nucleotide analog prodrug that, when converted to adefovir, inhibits HBV DNA polymerase. Both agents suppress viral replication and reduce hepatitis B viral load in infected patients.","oneSentence":"Telbivudine and adefovir dipivoxil are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting viral DNA polymerase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:25.558Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"HBeAg-positive chronic hepatitis B"},{"name":"HBeAg-negative chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT04724785","phase":"","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2020-12-01","conditions":"Sustained Virologic Response, Hepatitis B, Chronic","enrollment":10000},{"nctId":"NCT03366571","phase":"","title":"Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B","enrollment":600},{"nctId":"NCT01521975","phase":"PHASE4","title":"A Two-year Study of Telbivudine in HBeAg Negative Hepatitis","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2011-01-01","conditions":"Hepatitis B, Chronic","enrollment":360},{"nctId":"NCT00640588","phase":"PHASE3","title":"Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Hepatitis B, Chronic","enrollment":30},{"nctId":"NCT02826070","phase":"PHASE4","title":"EFFORT Further Extension Study","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2015-04","conditions":"Hepatitis B, Chronic","enrollment":130},{"nctId":"NCT00115245","phase":"PHASE3","title":"Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT01597934","phase":"PHASE4","title":"Antiviral Efficacy of Switching to ETV Plus TDF","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-08","conditions":"Chronic Hepatitis B","enrollment":104},{"nctId":"NCT01804387","phase":"PHASE4","title":"Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-05","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT00606099","phase":"PHASE4","title":"Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B","status":"WITHDRAWN","sponsor":"Novartis","startDate":"2007-11","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT00376259","phase":"PHASE3","title":"Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-01","conditions":"Hepatitis B","enrollment":43},{"nctId":"NCT00810524","phase":"PHASE4","title":"Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-01","conditions":"Hepatitis B, Chronic","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sebivo, LDT"],"phase":"marketed","status":"active","brandName":"Telbivudine, Adefovir dipivoxil","genericName":"Telbivudine, Adefovir dipivoxil","companyName":"Third Affiliated Hospital, Sun Yat-Sen University","companyId":"third-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telbivudine and adefovir dipivoxil are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting viral DNA polymerase. Used for Chronic hepatitis B infection, HBeAg-positive chronic hepatitis B, HBeAg-negative chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}